- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01874418
Biomarker Study to Diagnose Alzheimer's Disease (ADAM)
Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Alzheimer's disease is the most prevalent cause of dementia. A biomarker is a variable that are measured in vivo and indicate specific features of disease related molecular mechanisms and pathologic changes, including amyloid processing and aggregation, tau hyperphosphorylation, accumulation of neurofibrillary tangles, synaptic dysfunction, neurodegeneration, and loss of brain tissue.
We examine serum oligomeric beta-amyloid 42 and CSF monomeric beta-amyloid 42, total tau and phosphorylated tau, as well as PiB-PET, FDG-PET and brain MRI in 90 participants (30 normal controls, 30 patients with mild cognitive impairment, 30 patients with Alzheimer's disease).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Young Ho Park, MD
- Phone Number: 82-10-6287-8084
- Email: kumimesy@gmail.com
Study Contact Backup
- Name: SangYun Kim, MD, PhD
- Phone Number: 82-31-787-7462
- Email: neuroksy@snu.ac.kr
Study Locations
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of, 463-707
- Recruiting
- Seoul National University College of Medicine, Seoul National University Bundang Hospital
-
Contact:
- Young Ho Park, MD
- Phone Number: 82-10-6287-8084
- Email: kumimesy@gmail.com
-
Sub-Investigator:
- Youg Ho Park, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated written informed consent obtained from the subject or the subject's legally acceptable representative ( if applicable) in accordance with the local regularities.
- Both male and female, aged > 50 and <90, if women, must have no childbearing potential
- Controls did not have subjective memory complaints or any of 28 diseases and did not have a history suggestive of a decrease in cognitive function (stroke or transient ischemic attack, seizures, Parkinson's disease, multiple sclerosis, cerebral palsy, Huntington's disease, encephalitis, meningitis, brain surgery, vascular surgery of the brain, diabetes requiring insulin control, improperly managed hypertension, cancer diagnosed within the past 3 years excluding skin cancer, shortness of breath while sitting still, use of home oxygen, heart attack with changes in memory, walking, or solving problems lasting at least 24 hours afterwards, kidney dialysis, liver disease, hospitalization for mental or emotional problems in the past 5 years, current use of medications for mental or emotional problems, alcohol consumption greater than 3 drinks each day, drug abuse in the past 5 years, treatment for alcohol abuse in the past 5 years, unconsciousness for more than one hour other than during surgery, overnight hospitalization due to head injury, illness causing a permanent decrease in memory or other mental functions, trouble with vision that prevents reading ordinary print even with glasses, or difficulty understanding conversations because of hearing even with a hearing aid)
- The controls also had scores that were at least one standard deviation above the mean scores of the respective age- and education-matched population on the K-MMSE and an average score of 0.42 or less on the Korean Instrumental Activities of Daily Living (K-IADL)
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Biomarker study
Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
|
Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oligomeric beta-amyloid 42 in serum
Time Frame: baseline
|
To compare oligomeric beta-amyloid 42 in serum among normal controls, MCI and AD
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total tau concentration in CSF
Time Frame: baseline
|
To compare total tau concentration in CSF among normal controls, MCI and AD
|
baseline
|
Phosphorylated tau concentration in CSF
Time Frame: baseline
|
To compare phosphorylated tau concentration in CSF among normal controls, MCI and AD
|
baseline
|
Monomeric beta-amyloid 42 in CSF
Time Frame: baseline
|
To compare monomeric beta-amyloid 42 in CSF among normal controls, MCI and AD
|
baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PiB PET
Time Frame: baseline
|
To compare the uptake of PiB PET among normal controls, MCI and AD
|
baseline
|
FDG-PET
Time Frame: baseline
|
To compare the pattern of hypometabolism with FDG-PET among normal controls, MCI and AD
|
baseline
|
Brain MRI
Time Frame: baseline
|
To compare the volumetry and surface morphometry of brain T1-weighted MRI among normal controls, MCI and AD
|
baseline
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADAM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Biomarker
-
Institut Claudius RegaudCompletedTriple Negative Breast CancerFrance
-
St. Antonius HospitalRoche DiagnosticsRecruitingQuality of Life | Postoperative Complications | DeathNetherlands
-
University Medical Centre LjubljanaUniversity of LjubljanaActive, not recruitingCardiac ArrestSlovenia
-
National University Hospital, SingaporeUnknownAdvanced Solid TumorsSingapore
-
Assiut UniversityNot yet recruitingSystemic Lupus Erythematosus
-
First People's Hospital of HangzhouNot yet recruitingNon-small Cell Lung Cancer Stage IIIChina
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Fundacio PuigvertNucleix Ltd.UnknownUrologic Neoplasms | Urologic CancerSpain
-
Rothman Institute OrthopaedicsUnknownSurgical Site Infection | ZonulinUnited States